HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea · Delayed Price · Currency is KRW 3,510.00
-145.00 (-3.97%)
Aug 8, 2025, 3:30 PM KST
HLB Therapeutics Company Description
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally.
It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor.
It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers.
The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021.
HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam-si, South Korea.
HLB Therapeutics Co.,Ltd.
| Country | South Korea |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
Contact Details
Address: Parkview Office Tower Seongnam-si South Korea | |
| Phone | 82 3 1786 7800 |
| Website | hlbtherapeutics.co.kr |
Stock Details
| Ticker Symbol | 115450 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7115450009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ki Hong Ahn | Chief Executive Officer |